Search Results

You are looking at 111 - 120 of 524 items for :

  • "Adjuvant therapy" x
  • Refine by Access: All x
Clear All
Full access

Impact of Axillary Dissection Among Patients With Sentinel Node–Positive Breast Cancer Undergoing Mastectomy

James Sun, Brittany J. Mathias, Christine Laronga, Weihong Sun, Jun-Min Zhou, William J. Fulp, John V. Kiluk, and M. Catherine Lee

without records of adjuvant therapy were excluded. Patients were identified from a prospectively maintained breast cancer database at an NCI-designated Comprehensive Cancer Center. Clinicopathologic variables, including demographic information, pathology

Full access

Failure to Undergo Resection Following Neoadjuvant Therapy for Resectable Pancreatic Cancer: A Secondary Analysis of SWOG S1505

Jordan M. Cloyd, Sarah Colby, Katherine A. Guthrie, Andy M. Lowy, E. Gabrielle Chiorean, Phillip Philip, Davendra Sohal, and Syed Ahmad

Background Surgical resection followed by adjuvant therapy has historically been the recommended approach for patients with localized pancreatic ductal adenocarcinoma (PDAC). 1 , 2 Nevertheless, given the challenges in administering adjuvant

Full access

NCCN Guidelines® Insights: Non–Small Cell Lung Cancer, Version 2.2023

Featured Updates to the NCCN Guidelines

David S. Ettinger, Douglas E. Wood, Dara L. Aisner, Wallace Akerley, Jessica R. Bauman, Ankit Bharat, Debora S. Bruno, Joe Y. Chang, Lucian R. Chirieac, Malcolm DeCamp, Thomas J. Dilling, Jonathan Dowell, Gregory A. Durm, Scott Gettinger, Travis E. Grotz, Matthew A. Gubens, Aparna Hegde, Rudy P. Lackner, Michael Lanuti, Jules Lin, Billy W. Loo Jr, Christine M. Lovly, Fabien Maldonado, Erminia Massarelli, Daniel Morgensztern, Thomas Ng, Gregory A. Otterson, Sandip P. Patel, Tejas Patil, Patricio M. Polanco, Gregory J. Riely, Jonathan Riess, Steven E. Schild, Theresa A. Shapiro, Aditi P. Singh, James Stevenson, Alda Tam, Tawee Tanvetyanon, Jane Yanagawa, Stephen C. Yang, Edwin Yau, Kristina M. Gregory, and Miranda Hughes

ICIs. Immunotherapy Clinical Trial Data IMpower010, a phase III randomized trial, assessed adjuvant therapy with atezolizumab versus best supportive care in 1,005 patients with completely resected stage IB–IIIA NSCLC (staging

Full access

The First Documented Case of High-Grade Synovial Cell Sarcoma of the Rectum

Richard B. Hostetter, Min Yan, Houman Vaghefi, Kenneth Pennington, and Gary Cornette

higher total doses (60–66 Gy in 30–33 fractions). The advantage of adjuvant therapy is that the final pathology is clearly established. 3 Figure 6 Spindle tumor cells in bundle and fascicles (hematoxylin-eosin stain, original magnification x100

Full access

Multidisciplinary Management of Pancreatic Cancer

Margaret A. Tempero

pancreatic cancer, 80% of patients are diagnosed with advanced unresectable disease; 80% experience relapse after resection and adjuvant therapy; and median overall survival (OS) of patients with untreated metastatic disease is only 3 months. The “cure rate

Full access

Incorporating New Systemic Therapies in Kidney Cancer Treatment

Eric Jonasch

in Oncology (NCCN Guidelines) for Kidney Cancer. Adjuvant Therapy Three trials have been conducted in the adjuvant setting, 2 of which (ASSURE and PROTECT) showed negative results for adjuvant sunitinib, sorafenib, and pazopanib. A third trial

Full access

Ten Years of Progress in Colon Cancer Therapy

Paul F. Engstrom

2002, the NCCN panel advocated 5-fluorouracil (5-FU)/leucovorin adjuvant therapy for stage III or node-positive disease and 5-FU leucovorin with or without irinotecan (IFL) as first-line therapy for metastatic disease. Second-line therapies for

Full access

Locally Recurrent Endometrial Cancer: A Case Report

Srinivas K. Tantravahi, and Theresa L. Werner

pathologically staged as FIGO stage IA (pT1a pN0 Mx). She received no adjuvant therapy. She returned 3 months later with recurrent vaginal bleeding. A 2-cm friable mass was visualized at the apex of the vaginal cuff on pelvic examination and was resected

Full access

Combined Modality Therapy of Localized Gastric and Esophageal Cancers

Prajnan Das, Norio Fukami, and Jaffer A. Ajani

. 29. Gunderson LL Sosin H . Adenocarcinoma of the stomach: areas of failure in a re-operation series (second or symptomatic look) clinicopathologic correlation and implications for adjuvant therapy . Int J Radiat Oncol Biol Phys 1982 ; 8 : 1

Full access

Take Your Medicine

Harold J. Burstein

percentage. Of course, a few caveats are warranted. The bulk of these reports are derived from studies of women taking adjuvant therapy for hormone receptor-positive breast cancer. Such patients often have a favorable prognosis and might reasonably be